DNA methylation inhibitor, decitabine, promotes MGC803 gastric cancer cell migration and invasion via the upregulation of NEDD4‑1

Li,Dong; Xu,Chun‑Yan; Cui,Rong‑Jun; Tang,Jie‑Bing; Sun,Hui; Yang,Zheng‑Kai; Bu,Jing‑Yi; Lin,Ping; Huang,Ning; Du,Yan‑Dan; Yu,Xiao‑Guang

doi:10.3892/mmr.2015.4424

DNA methylation inhibitor, decitabine, promotes MGC803 gastric cancer cell migration and invasion via the upregulation of NEDD4‑1

Authors:
- Dong Li
- Chun‑Yan Xu
- Rong‑Jun Cui
- Jie‑Bing Tang
- Hui Sun
- Zheng‑Kai Yang
- Jing‑Yi Bu
- Ping Lin
- Ning Huang
- Yan‑Dan Du
- Xiao‑Guang Yu
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Clinical Laboratory, The Second Clinical Medical School of Inner Mongolia University for The Nationalities, (Inner Mongolia Forestry General Hospital), Hulunbuir, Inner Mongolia 022150, P.R. China
Published online on: October 9, 2015 https://doi.org/10.3892/mmr.2015.4424
Pages: 8201-8208

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is the fourth most common cancer type and the second leading cause of cancer‑associated mortality worldwide. Metastasis is a crucial feature of its progression. DNA methylation provides a key epigenetic signature in the epigenetic regulation pathway, and is implicated in transcriptional regulation. CpG sites, which are associated with gene transcriptional activity, are underrepresented in the mammalian genome and tend to be clustered within CpG islands (CGIs) located in the vicinity of the transcription start sites of the majority of the protein‑coding genes in humans. The DNA methylation inhibitor, decitabine (DAC), has been demonstrated to be active in hematological disorders. The majority of previous studies in cancer cells demonstrated that DAC inhibits cell proliferation and the motility of the cells. However, since demethylation across the entire genome alters the expression of a large number of genes, the effects of DAC in different tumor cell types are difficult to accurately predict. Neural precursor cell‑expressed, developmentally downregulated (NEDD)4‑1, a member of the NEDD4 family, which belongs to the E3‑ubiquitin ligase family, was reported to be highly expressed in a wide range of tumor types, and it activates the phosphoinositide 3‑kinase/Akt pathway by degrading phosphatase and tensin homolog. NEDD4‑1 promotes the migration and invasion of glioma cells via the ubiquitination and subsequent degradation of cyclic nucleotide‑Ras guanine nucleotide exchange factors (CNrasGEFs). In gastric cardia adenocarcinoma, NEDD4‑1 acts as an exceptional prognostic biomarker. In the present study, DAC was revealed to promote the invasive properties of MGC803 gastric cancer cells. NEDD4‑1 targeted the CNrasGEF‑mediated DAC invasion‑promoting activity in MGC803 cells, and CGI methylation in neither the NEDD4 promoter nor the first intron was demonstrated to be associated with this effect. The results of the present study revealed that DAC exerts variable effects in different gastric cancer cell lines and may provide a reference for DAC administration in the clinic.

View Figures

View References

1	Melton SD, Genta RM and Souza RF: Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms. Nat Rev Gastroenterol Hepatol. 7:620–628. 2010.PubMed/NCBI
2	Correa P and Houghton J: Carcinogenesis of Helicobacter pylori. Gastroenterology. 133:659–672. 2007. View Article : Google Scholar : PubMed/NCBI
3	Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345:725–730. 2001. View Article : Google Scholar : PubMed/NCBI
4	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
5	Robertson KD: DNA methylation, methyltransferases and cancer. Oncogene. 20:3139–3155. 2001. View Article : Google Scholar : PubMed/NCBI
6	Guo M and Yan W: Epigenetics of gastric cancer. Methods Mol Biol. 1238:783–799. 2015. View Article : Google Scholar
7	Illingworth RS, Gruenewald-Schneider U, Webb S, Kerr AR, James KD, Turner DJ, Smith C, Harrison DJ, Andrews R and Bird AP: Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLoS Genet. 6:e10011342010. View Article : Google Scholar : PubMed/NCBI
8	Nie J, Liu L, Li X and Han W: Decitabine, a new star in epigenetic therapy: The clinical application and biological mechanism in solid tumors. Cancer Lett. 354:12–20. 2014. View Article : Google Scholar : PubMed/NCBI
9	Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer. 106:1794–1803. 2006. View Article : Google Scholar : PubMed/NCBI
10	Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J and Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 103:1635–1640. 2004. View Article : Google Scholar
11	Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ and Talpaz M: Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 86:2632–2641. 1999. View Article : Google Scholar : PubMed/NCBI
12	Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, et al: Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 98:522–528. 2003. View Article : Google Scholar : PubMed/NCBI
13	Lubbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, et al: Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phaseIII study of the European organisation for research and treatment of cancer Leukemia group and the German MDS study group. J Clin Oncol. 29:1987–1996. 2011. View Article : Google Scholar
14	Shin DY, Kim GY, Kim CG, Kim WJ, Kang HS and Choi YH: Anti-invasive effects of decitabine, a DNA methyltransferase inhibitor, through tightening of tight junctions and inhibition of matrix metalloproteinase activities in AGS human gastric carcinoma cells. Oncol Rep. 28:1043–1050. 2012.PubMed/NCBI
15	Liu WH, Sang MX, Hou SY, Zhang C and Shan BE: Low-dose decitabine induces MAGE-A expression and inhibits invasion via suppression of NF-κB2 and MMP2 in Eca109 cells. Biomed Pharmacother. 68:745–750. 2014. View Article : Google Scholar : PubMed/NCBI
16	Jiao F, Bai SY, Ma Y, Yan ZH, Yue Z, Yu Y, Wang X and Wang J: DNA methylation of heparanase promoter influences its expression and associated with the progression of human breast cancer. PLoS One. 9:e921902014. View Article : Google Scholar : PubMed/NCBI
17	Borges S, Döppler HR and Storz P: A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells. Breast Cancer Res Treat. 144:79–91. 2014. View Article : Google Scholar : PubMed/NCBI
18	Rougier JS, Albesa M, Abriel H and Viard P: Neuronal precursor cell-expressed developmentally downregulated 4-1 (NEDD4-1) controls the sorting of newly synthesized Ca (V) 1.2 calcium channels. J Biol Chem. 286:8829–8838. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kwak YD, Wang B, Pan W, Xu H, Jiang X and Liao FF: Functional interaction of phosphatase and tensin homologue (PTEN) with the E3 ligase NEDD4-1 during neuronal response to zinc. J Biol Chem. 285:9847–9857. 2010. View Article : Google Scholar : PubMed/NCBI
20	Liu Y, Oppenheim RW, Sugiura Y and Lin W: Abnormal development of the neuromuscular junction in Nedd4-deficient mice. Dev Biol. 330:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
21	Kawabe H, Neeb A, Dimova K, Young SM Jr, Takeda M, Katsurabayashi S, Mitkovski M, Malakhova OA, Zhang DE, Umikawa M, et al: Regulation of Rap2A by the ubiquitin ligase Nedd4-1 controls neurite development. Neuron. 65:358–372. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kawabe H and Brose N: The ubiquitin E3 ligase Nedd4-1 controls neurite development. Cell Cycle. 9:2477–2478. 2010. View Article : Google Scholar : PubMed/NCBI
23	Lackovic J, Howitt J, Callaway JK, Silke J, Bartlett P and Tan SS: Differential regulation of Nedd4 ubiquitin ligases and their adaptor protein Ndfip1 in a rat model of ischemic stroke. Exp Neurol. 235:326–335. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kwak YD, Wang B, Li JJ, Wang R, Deng Q, Diao S, Chen Y, Xu R, Masliah E, Xu H, et al: Upregulation of the E3 ligase NEDD4-1 by oxidative stress degrades IGF-1 receptor protein in neurodegeneration. J Neurosci. 32:10971–10981. 2012. View Article : Google Scholar : PubMed/NCBI
25	Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, et al: NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 128:129–139. 2007. View Article : Google Scholar : PubMed/NCBI
26	Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R, Botti G, Pirozzi P, Rocco G, De Rosa N and Viglietto G: Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol. 177:2622–2634. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kim SS, Yoo NJ, Jeong EG, Kim MS and Lee SH: Expression of NEDD4-1, a PTEN regulator, in gastric and colorectal carcinomas. APMIS. 116:779–784. 2008. View Article : Google Scholar : PubMed/NCBI
28	Zhang H, Nie W, Zhang X, Zhang G, Li Z, Wu H, Shi Q, Chen Y, Ding Z, Zhou X and Yu R: NEDD4-1 regulates migration and invasion of glioma cells through CNrasGEF ubiquitination in vitro. PLoS One. 8:e827892013. View Article : Google Scholar : PubMed/NCBI
29	Sun A, Yu G, Dou X, Yan X, Yang W and Lin Q: Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis. Mol Cancer. 13:2482014. View Article : Google Scholar : PubMed/NCBI
30	Lin F, Lin P, Zhao D, Chen Y, Xiao L, Qin W, Li D, Chen H, Zhao B, Zou H, et al: Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif. 45:207–216. 2012. View Article : Google Scholar : PubMed/NCBI
31	Wang X, Wang H, Jiang N, Lu W, Zhang XF and Fang JY: Effect of inhibition of MEK pathway on 5-aza-deoxycytidine-suppressed pancreatic cancer cell proliferation. Genet Mol Res. 12:5560–5573. 2013. View Article : Google Scholar : PubMed/NCBI
32	Wang B, Li H, Yang R, Zhou S and Zou S: Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts. Oncol Lett. 8:1919–1924. 2014.PubMed/NCBI
33	Li LC and Dahiya R: MethPrimer: Designing primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002. View Article : Google Scholar : PubMed/NCBI
34	Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, Yong WH, Li N, Li G and Kruse CA: et al Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro Oncol. Sep 1–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
35	Yan W, Herman JG and Guo M: Epigenome-based personalized medicine in human cancer. Epigenomics. Sep 7–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI